🇺🇸 FDA
Patent

US 11524942

Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine

granted A61PA61P19/02A61P25/28

Quick answer

US patent 11524942 (Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine) held by VTV THERAPEUTICS LLC expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VTV THERAPEUTICS LLC
Grant date
Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P19/02, A61P25/28